283 related articles for article (PubMed ID: 33150733)
1. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
Han Y; Mu D; Liu T; Zhang H; Zhang J; Li S; Wang R; Du W; Hui Z; Zhang X; Ren X
Thorac Cancer; 2021 Jan; 12(2):145-152. PubMed ID: 33150733
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Zhou L; Xiong Y; Wang Y; Meng Y; Zhang W; Shen M; Zhang X; Li S; Ren B; Li R; Han Y; Zhang J; Cao S; Du W; Sun Q; Wei F; An X; Yang L; Zhang Y; Ma W; Xu W; Zhang Y; Jiang J; Xu X; Xia J; Liu L; Ren X
Clin Lung Cancer; 2022 Dec; 23(8):709-719. PubMed ID: 35995696
[TBL] [Abstract][Full Text] [Related]
4. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
5. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
6. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
7. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
9. Combination of PD-1 blockade and RetroNectin
Zhao L; Han L; Zhang Y; Li T; Yang Y; Li W; Shang Y; Lin H; Gao Q
Immunotherapy; 2018 Nov; 10(15):1315-1323. PubMed ID: 30350739
[TBL] [Abstract][Full Text] [Related]
10. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
12. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
Front Oncol; 2022; 12():713476. PubMed ID: 35646685
[TBL] [Abstract][Full Text] [Related]
13. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
14. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.
Chen J; Chen Y; Feng F; Chen C; Zeng H; Wen S; Xu X; He J; Li J
J Thorac Dis; 2018 Dec; 10(12):6711-6721. PubMed ID: 30746216
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer.
Tian L; Wang W; Yu B; Zhang G
J BUON; 2020; 25(5):2364-2370. PubMed ID: 33277857
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
